TRML Company Profile and Key Details

Tourmaline Bio, Inc. has 25.69 million shares outstanding. The public float is 13.10 million shares, elevated short interest at 11.56% of float. This equals 2.65 million shares. The short ratio is 14.74 days. Institutional investors hold 115.46% of the float. Insiders own 21.93%.

The stock is currently trading near its 52-week high $11.56 and $48.27. With a market capitalization of about $1.23 billion, Tourmaline Bio, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.58). Key stats such as the average daily volume over the past year has been around 925.78 thousand shares, in line with its 52-week average. Headquartered in New York City, NY, Tourmaline Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sandeep C. Kulkarni, the company employs approximately 74 people and listed since May 07, 2021. Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases.

Tourmaline Bio, Inc. generated EPS of -$3.44 over the past year. Five-year average earnings growth is 8.04%. Wall Street analysts project EPS growth of -20.69% annually over the next five years. The latest quarter delivered EPS of -$0.78. The next quarter is forecast at -$0.93. Next year's EPS is expected at $13.17. Analyst sentiment is neutral. Analyst rating data shows there are 3 Strong Buy ratings, 3 Buy ratings, 9 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $70.00 to $42.00. The high target offers 45.89% upside. The low target suggests -12.46% downside. The mean target is $49.97. This offers 4.15% upside. Tourmaline Bio, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 06, 2025, missed forecasts by -18.75%. The prior quarter beat by -4.26%. Over the last six quarters, Apple has recorded several small beats. These include -5.56% in August 08, 2024.

Short-term trend indicators are bearishly aligned (SMA20 0.16%, SMA50 17.94%, SMA200 111.02%). The stock’s 14-day RSI is 89.35 (overbought), while the ATR of 0.28 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -0.6% below its high and over 315.05% above its low.

Tourmaline Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.19. This means the shares are trading above this model’s fair value.

Tourmaline Bio, Inc. trades at a P/E ratio of -13.97, slightly below the S&P 500 average, with a price-to-sales ratio of 30816.28 and a price-to-book ratio of 4.77 trading at moderately above to book value. The P/FCF stands at -14.28, also below market averages.

Our AI price prediction model suggests that Tourmaline Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.27%, with price expected at $48.11 by November 10, 2025, within a range of $46.01 to $50.47 3-Month Outlook: Projected rise of 39.12%, reaching $66.75 by January 23, 2026, with a range of $65.94 to $67.86. 1-Year Outlook: Projected loss of -3.21%, with price at $46.44 by October 27, 2026, within a range of $42.94 to $49.50.

Tourmaline Bio, Inc. (NASDAQ:TRML) shares are up 136.59% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Tourmaline Bio, Inc. trading at a premium to the broader market with a P/E of -13.97. Analyst sentiment is cautious, with the majority of ratings in Market Perform territory and a mean price target of $48.50, suggesting 1.08% upside. Our AI forecast model points to short-term strength (0.27% over two weeks), a medium-term rise (39.12% over three months), and a longer-term loss (-3.21% over one year), with expected trading ranges indicating moderate volatility.